CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质母细胞瘤中的信号通路失调与治疗耐药：分子机制与新兴治疗靶点

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.

儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

胶质瘤中的 NK 细胞功能障碍：从免疫逃逸到免疫治疗

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.

重定向溶瘤病毒经工程化改造以重塑肿瘤微环境用于胶质母细胞瘤免疫治疗

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.

免疫细胞特征与多种恶性及非恶性 CNS 疾病风险之间的因果关联：孟德尔随机化与单细胞转录组分析

Causal Association Between Immune Cell Traits and Risk of Multiple Malignant and Nonmalignant CNS Diseases: A Mendelian Randomization and Single-Cell

我们的研究结果确定了不同 ICT 对恶性和非恶性脑疾病的因果效应，并强调了神经炎症在其病因学中的关键作用。结合 eQTL 和 scRNA-seq 的证据，GBM 可以得到更好的表征和管理。

免疫健全小鼠胶质瘤模型中表达 CAR 的 T 细胞、NK 细胞、NKT 细胞与巨噬细胞的比较评估

Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model.

这些数据为在免疫功能健全的胶质瘤环境中哪些免疫细胞能介导有效的抗胶质瘤应答提供了有价值的依据。

体外评估基因未修饰的配体武装异体 NK 细胞治疗 EGFR 阳性胶质母细胞瘤

In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma.

针对多形性胶质母细胞瘤的 NK 细胞免疫治疗潜在分子靶点

Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.

革新胶质母细胞瘤治疗：现代治疗方法的全面概述

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

双靶向胶质母细胞瘤细胞的双特异性杀伤细胞衔接器靶向 EGFR 和 ErbB2（HER2）促进 NKG2D-CAR 工程化 NK 细胞的有效清除

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D